ADMINISTRATION OF LOADING DOSES OF STATINS FOR PREVENTION OF CONTRAST-INDUCED KIDNEY INJURY DURING ENDOVASCULAR INTERVENTIONS IN PATIENTS WITH ISCHEMIC HEART DISEASE

Percutaneous coronary interventions have become a key method of revascularization in patients with coronary artery disease. Contrast-induced nephropathy is one of the main complications in patients who undergo coronary angiography and percutaneous coronary intervention. Loading doses of statins are often used for the purpose of nephroprotection. However, a clear available algorithm for prescribing statins for the prevention of acute contrast-induced kidney injury has not been identified. 

The purpose: to evaluate the effectiveness of high loading doses of statins (atorvastatin and rosuvastatin) to prevent acute contrast-induced kidney injury in patients with chronic ischemic heart disease during planned endovascular treatment.
Material and Methods. Patients with clinical manifestations of FC II and III angina pectoris and hemodynamically significant stenoses of the coronary arteries were referred for a planned endovascular myocardial revascularization. Two groups of patients were assigned based on the intake of synthetic statins: atorvastatin and rosuvastatin. Before the endovascular intervention, patients were administered with high loading doses of statins. All patients underwent general clinical examination, routine assessment of creatinine levels, other blood tests, assessment of glomerular filtration rate, and control of lipid profile of blood.
Conclusion. The incidence rate of contrast-induced kidney injury in patients with coronary artery disease, administered with loading doses of rosuvastatin, in the course of planned percutaneous coronary intervention was lower compared with the loading therapy of atorvastatin: 3.33 and 12.12%, respectively. On average, an increase in creatinine concentration to the maximum level occurred more often in the group of patients administered with a loading dose of atorvastatin than in the other group administered with a loading dose of rosuvastatin (14.3 versus 8.1%, p=0.024). A decrease in renal function in terms of GFR of less than 60 mL/min/1.73 m2 on day 5 was observed in 12 patients (34.3%) in the first group versus 9 patients (27.3%) in the second group. Therapy with loading doses of rosuvastatin before endovascular myocardial revascularization was more effective than treatment of patients with atorvastatin. 

1. Guideline update for percutaneous coronary intervention. A Report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J. Am. Coll. Cardiol. 2006; 47: 1–121.

2. The World Health Organization the top ten causes of death fact sheet. 2012.

3. Bokeria L. A., Alekyan B. G., Sargsyan A. Z. Endovascular treatment of patients with a non-coronary coronary bed. Thoracic and cardiovascular surgery. 2013; 6: 19‑25 (In Russ.).

4. Prasad V., Gandhi D., Stokum C., Miller T., Jindal G. Incidence of contrast material-induced nephropathy after neuroendovascular procedures. Radiology. 2014; 273: 853–858.

5. Kim J. H., Yang J. H., Choi S. H., Song Y. B., Hahn J. Y., Choi J. H., Lee S. H., Gwon H. C. Predictors of outcomes of contrast-induced acute kidney injury after percutaneous coronary intervention in patients with chronic kidney disease. Am. J. Cardiol. 2014; 114: 1830–1835.

6. Mc Cullough P. A. Contrast-induced acute kidney injury. J. Am. Coll. Cardiol. 2008; 51: 1419–1428.

7. Pyxaras S. A., Sinagra G., Mangiacapra F., Perkan A., Di Serafino L., Vitrella G., Rakar S., De Vroey F., Santangelo S., Salvi A., Toth G., Bartunek J., De Bruyne B., Wijns W., Barbato E. Contrast-induced nephropathy in patients undergoing primary percutaneous coronary intervention without acute left ventricular ejection fraction impairment. Am. J. Cardiol. 2013; 111: 684–688.

8. Marenzi G., Lauri G., Assanelli E., Campodonico J., De Metrio M., Marana I., Grazi M., Veglia F., Bartorelli A. L. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J. Am. Coll. Cardiol. 2004; 44: 1780–1785.

9. Brown J. R., Malenka D. J., DeVries J. T., Robb J. F., Jayne J. E., Friedman B. J., Hettleman B. D., Niles N. W., Kaplan A. V., Schoolwerth A. C., Thompson C. A. Transient and persistent renal dysfunction are predictors of survival after percutaneous coronary intervention: insights from the Dartmouth Dynamic Registry. Catheter Cardiovasc. Interv. 2008; 72: 347–354.

10. Vershinina E. O., Repin A. N. Contrast-induced nephropathy in planned endovascular interventions on the coronary arteries. Siberian Medical Journal. 2016; 31(3): 61–67 (In Russ.).

11. Clinical recommendations of ESC / EACTS on myocardial revascularization. 2014 (In Russ.).

12. Comparison of Usefulness of Simvastatin 20 mg Versus 80 mg in Preventing Contrast-Induced Nephropathy in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. Am. J. Cardiol. 2009; 104(4): 514–519.

13. Li Y., Liu Y., Fu L., Mei C., Dai B. Efficacy of short-term high-dose statin in preventing contrast-induced nephropathy: a metaanalysis of seven randomized controlled trials. PLoS One. 2012; 7(4): 344–350.

14. Tropeano F., Leoncini M., Toso A., Maioli M., Dabizzi L., Biagini D., Villani S., Bellandi F. Impact of Rosuvastatin in Contrast-Induced Acute Kidney Injury in the Elderly: Post Hoc Analysis of the PRATO-ACS Trial. J. Cardiovasc. Pharmacol. Ther. 2016; 21(2): 159–166.

15. Hyun Goo Lee, Won Ki Kim, Je Young Yeon, Jong Soo Kim, Keon Ha Kim, Pyoung Jeon, Seung Chyul Hong. Contrast-Induced Acute Kidney Injury after Coil Embolization for Aneurysmal Subarachnoid Hemorrhage. Yonsei Med. J. 2018; 59(1): 107–112.

16. Solomon R., Dauerman H. L. Contrast-induced acute kidney injury. Circulation. 2010; 122: 2451–2455.

17. Solomon R. J., Natarajan M. K., Doucet S., Sharma S. K., Staniloae C. S., Katholi R. E., Gelormini J. L., Labinaz M., Moreyra A. E.; Investigators of the CARE Study. Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation. 2007; 115: 3189–3196.

18. Marenzi G., Assanelli E., Campodonico J., Lauri G., Marana I., De Metrio M., Moltrasio M., Grazi M., Rubino M., Veglia F., Fabbiocchi F., Bartorelli A. L. Contrast volume during primary percutaneous coronary intervention and subsequent contrastinduced nephropathy and mortality. Ann. Intern. Med. J. 2009; 150: 170–177.

19. Mehran R., Aymong E. D., Nikolsky E., Lasic Z., Iakovou I., Fahy M., Mintz G. S., Lansky A. J., Moses J. W., Stone G. W., Leon M. B., Dangas G. A simple risk score for prediction of contrast induced nephropathy after percutaneous coronary intervention: development and initial validation. J. Am. Coll. Cardiol. 2004; 44: 1393–1399.

20. Wijns W., Kolh P., Danchin N., Di Mario C., Falk V., Folliguet T., Garg S., Huber K., James S., Knuuti J., Lopez-Sendon J., Marco J. Guidelines on myocardial revascularization. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio Thoracic Surgery (EACTS). Eur. Heart J. 2010; 31: 2501–2555.